Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.
Fc-gamma receptor
TNF blockers
polymorphism
responsiveness
rheumatoid arthritis
Journal
Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
27
10
2022
accepted:
24
12
2022
medline:
7
6
2023
pubmed:
16
3
2023
entrez:
15
3
2023
Statut:
epublish
Résumé
Single nucleotid polymorphisms (SNPs) of Fc-gamma receptors (FcgRs), by inducing a variation of their affinity to the Fc-region of immunoglobulins, might influence the efficacy of Fc-containing biologics prescribed in rheumatoid arthritis (RA). Our aim was to investigate associations of A cross-sectional, observational and analytic multicentric cohort study was conducted in a group of 47 Tunisian RA patients treated with (etanercept [ETA], adalimumab [ADL] and infliximab [IFX]). Treatment outcome was evaluated after 6 months. The analytic study including all types of TNFi showed that Identifying reliable biomarkers of response to biologics in RA is necessary to improve responsiveness, preserve joints' functions and structure, and reduce treatment's cost. Our study showed that FCGR3A and FCGR3B polymorphisms might have an impact on TNFis' response in RA Tunisian patients since bad response was more frequent in homozygous carriers of high affinity alleles FCGR3A-V and FCGR3B-NA1.
Identifiants
pubmed: 36919284
pii: dmpt-2022-0176
doi: 10.1515/dmpt-2022-0176
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
FCGR3B protein, human
0
Receptors, IgG
0
GPI-Linked Proteins
0
FCGR2A protein, human
0
FCGR3A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-162Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Alfonso-Cristancho, R, Armstrong, N, Arjunji, R, Riemsma, R, Worthy, G, Ganguly, R, et al.. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clin Rheumatol 2017;36:25–34. https://doi.org/10.1007/s10067-016-3435-2 .
doi: 10.1007/s10067-016-3435-2
Hayes, JM, Frostell, A, Karlsson, R, Müller, S, Martín, SM, Pauers, M, et al.. Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab. Mol Cell Proteomics 2017;16:1770–88. https://doi.org/10.1074/mcp.m117.066944 .
doi: 10.1074/mcp.m117.066944
Lee, YH, Bae, SC. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2016;36:837–44. https://doi.org/10.1007/s00296-016-3476-5 .
doi: 10.1007/s00296-016-3476-5
Lee, YH, Bae, SC, Song, GG. Functional FCGR3A 158 V/F and IL-6 – 174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. Rheumatol Int 2014;34:1409–15. https://doi.org/10.1007/s00296-014-3015-1 .
doi: 10.1007/s00296-014-3015-1
Li, X, Ptacek, TS, Brown, EE, Edberg, JC. Fcγ receptors: structure, function and role as genetic risk factors in SLE. Gene Immun 2009;10:380–9. https://doi.org/10.1038/gene.2009.35 .
doi: 10.1038/gene.2009.35
Brown, EE, Edberg, JC, Kimberly, RP. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 2007;40:567–81. https://doi.org/10.1080/08916930701763710 .
doi: 10.1080/08916930701763710
Hogarth, PM, Anania, JC, Wines, BD. The FcγR of humans and non-human primates and their interaction with IgG: implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies. Curr Top Microbiol Immunol 2014;382:321–52. https://doi.org/10.1007/978-3-319-07911-0_15 .
doi: 10.1007/978-3-319-07911-0_15
Marotte, H, Cimaz, R. Etanercept – TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert OpinBiolTher 2014;14:569–72. https://doi.org/10.1517/14712598.2014.896334 .
doi: 10.1517/14712598.2014.896334
Cartron, G, Dacheux, L, Salles, G, Solal-Celigny, P, Bardos, P, Colombat, P, et al.. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–8. https://doi.org/10.1182/blood.v99.3.754 .
doi: 10.1182/blood.v99.3.754
Sfar, I, Dhaouadi, T, Habibi, I, Abdelmoula, L, Makhlouf, M, Ben Romdhane, T, et al.. Functional polymorphisms of PTPN22 and FcgR genes in tunisian patients with rheumatoid arthritis. Arch Inst Pasteur Tunis 2009;86:51–62.
Criswell, LA, Lum, RF, Turner, KN, Woehl, B, Zhu, Y, Wang, J, et al.. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750–6. https://doi.org/10.1002/art.20469 .
doi: 10.1002/art.20469
Tutuncu, Z, Kavanaugh, A, Zvaifler, N, Corr, M, Deutsch, R, Boyle, D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005;52:2693–6. https://doi.org/10.1002/art.21266 .
doi: 10.1002/art.21266
Kastbom, A, Bratt, J, Ernestam, S, Lampa, J, Padyukov, L, Söderkvist, P, et al.. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:448–52. https://doi.org/10.1002/art.22390 .
doi: 10.1002/art.22390
Rooryck, C, Barnetche, T, Richez, C, Laleye, A, Arveiler, B, Schaeverbeke, T. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008;26:340–2.
Cañete, JD, Suárez, B, Hernández, MV, Sanmartí, R, Rego, I, Celis, R, et al.. Influence of variants of Fc gamma receptors IIA and IIIA on the American college of rheumatology and European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1547–52. https://doi.org/10.1136/ard.2008.096982 .
doi: 10.1136/ard.2008.096982
Morales-Lara, MJ, Conesa-Zamora, P, García-Simón, MS, Pedrero, F, Santaclara, V, Perez-Guillermo, M, et al.. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scand J Rheumatol 2010;39:518–20. https://doi.org/10.3109/03009741003781969 .
doi: 10.3109/03009741003781969
Sarsour, K, Greenberg, J, Johnston, JA, Nelson, DR, O’Brien, LA, Oddoux, C, et al.. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. Clin Exp Rheumatol 2013;31:189–94.
Montes, A, Perez-Pampin, E, Narváez, J, Cañete, JD, Navarro-Sarabia, F, Moreira, V, et al.. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenetics Genom 2014;24:238–45. https://doi.org/10.1097/fpc.0000000000000042 .
doi: 10.1097/fpc.0000000000000042
Avila-Pedretti, G, Tornero, J, Fernández-Nebro, A, Blanco, F, González-Alvaro, I, Cañete, JD, et al.. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS One 2015;10:e0122088. https://doi.org/10.1371/journal.pone.0122088 .
doi: 10.1371/journal.pone.0122088
Dávila-Fajardo, CL, van der Straaten, T, Baak-Pablo, R, Medarde Caballero, C, Cabeza Barrera, J, Huizinga, TW, et al.. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics 2015;16:373–81. https://doi.org/10.2217/pgs.14.178 .
doi: 10.2217/pgs.14.178
Montes, A, Perez-Pampin, E, Joven, B, Carreira, P, Fernández-Nebro, A, Del Carmen Ordóñez, M, et al.. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics 2015;16:333–45. https://doi.org/10.2217/pgs.14.175 .
doi: 10.2217/pgs.14.175
Sun, Y, Mo, L, Feng, X, Yang, D, Tan, T, Zeng, L, et al.. Association of Fcgamma receptor type 2A and 3A genotypes with rheumatoid arthritis in Chinese population. Pharmacogenomics 2017;18:255–64. https://doi.org/10.2217/pgs-2016-0159 .
doi: 10.2217/pgs-2016-0159
Sanders, LA, Feldman, RG, Voorhorst-Ogink, MM, de Haas, M, Rijkers, GT, Capel, PJ, et al.. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995;63:73–81. https://doi.org/10.1128/iai.63.1.73-81.1995 .
doi: 10.1128/iai.63.1.73-81.1995
Wu, J, Edberg, JC, Redecha, PB, Bansal, V, Guyre, PM, Coleman, K, et al.. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059–70. https://doi.org/10.1172/jci119616 .
doi: 10.1172/jci119616
Kobayashi, T, van der Pol, WL, van de Winkel, JG, Hara, K, Sugita, N, Westerdaal, NA, et al.. Relevance of IgG receptor IIIb (CD16) polymorphism to handling of porphyromonas gingivalis: implications for the pathogenesis of adult periodontitis. J Periodontal Res 2000;35:65–73. https://doi.org/10.1034/j.1600-0765.2000.035002065.x .
doi: 10.1034/j.1600-0765.2000.035002065.x
Tracey, D, Klareskog, L, Sasso, EH, Salfeld, JG, Tak, PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–79. https://doi.org/10.1016/j.pharmthera.2007.10.001 .
doi: 10.1016/j.pharmthera.2007.10.001
Bek, S, Bojesen, AB, Nielsen, JV, Sode, J, Bank, S, Vogel, U, et al.. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J 2017;17:403–11. https://doi.org/10.1038/tpj.2017.26 .
doi: 10.1038/tpj.2017.26
Louis, E, El Ghoul, Z, Vermeire, S, Dall’Ozzo, S, Rutgeerts, P, Paintaud, G, et al.. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther 2004;19:511–9. https://doi.org/10.1111/j.1365-2036.2004.01871.x .
doi: 10.1111/j.1365-2036.2004.01871.x
Louis, EJ, Watier, HE, Schreiber, S, Hampe, J, Taillard, F, Olson, A, et al.. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn’s disease: a subanalysis of the ACCENT I study. Pharmacogenetics Genom 2006;16:911–4. https://doi.org/10.1097/01.fpc.0000230421.12844.fd .
doi: 10.1097/01.fpc.0000230421.12844.fd
Tomita, K, Chiba, T, Sugai, T, Habano, W. Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn’s disease. Hepato-Gastroenterology 2010;57:535–9.
Moroi, R, Endo, K, Kinouchi, Y, Shiga, H, Kakuta, Y, Kuroha, M, et al.. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity. Immunogenetics 2013;65:265–71. https://doi.org/10.1007/s00251-013-0679-8 .
doi: 10.1007/s00251-013-0679-8